NSTEMI Mortality Rates and Predictors

Introduction to NSTEMI Mortality

• NSTEMI mortality varies significantly by timeframe and risk profile, with in-hospital mortality ranging from 1.0-3.6%, 30-day mortality from 1.5-4.9%, 6-month mortality around 7-12%, and 1-year mortality from 2.2-3.9%, with higher rates observed in lower-income countries and patients with multiple comorbidities 1, 2, 3, 4

Medium-Term Mortality (6 Months to 1 Year)

• In the FRISC-II trial, the 1-year mortality rate was 2.2% with an invasive strategy versus 3.9% with a conservative strategy (p=0.016) 1, 2, 3, 5, 6, 7, 8
• In the TACTICS-TIMI 18 trial, the 6-month death or MI rate was 7.3% with an invasive strategy versus 9.5% with a conservative strategy (p<0.05) 1, 2, 5, 6, 7, 8
• The composite endpoint of death, MI, or rehospitalization at 6 months occurred in 15.9% with an invasive strategy versus 19.4% with a conservative strategy (p=0.025) 1, 2, 5, 6, 7, 8

Long-Term Mortality (Beyond 1 Year)

• At 5 years, FRISC-II demonstrated a mortality benefit with an invasive strategy (HR 0.81, p=0.009), though the benefit was confined to men, nonsmokers, and patients with 2 or more risk factors 1, 2, 3, 5, 6, 7, 8

Risk Stratification and Mortality Prediction

• The TIMI Risk Score provides validated mortality estimates for NSTEMI, with scores ranging from 0-1 (4.7% risk of death, MI, or urgent revascularization) to 6-7 (40.9% risk) 2, 4, 9
• The GRACE Risk Score offers in-hospital mortality predictions ranging from 0.2% (score <80) to 52% (score ≥240) 9

Important Clinical Caveats

• Contemporary mortality rates have improved dramatically, with the 2020 ESC Guidelines reporting a 6-month mortality decrease from 17.2% in 1995 to 6.3% in 2015 (adjusted HR 0.40) 4
• Risk stratification is critical, as mortality benefit from invasive strategy is primarily seen in medium- and high-risk patients (troponin >0.01 ng/mL, ST-segment deviation, or TIMI score >3) 1, 2, 5, 6, 7, 8